RT Journal Article
SR Electronic
T1 Lack of Association of Proteinuria and Clinical Outcome in Patients Treated with Bevacizumab for Metastatic Colorectal Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 309
OP 316
VO 33
IS 1
A1 IWASA, SATORU
A1 NAKAJIMA, TAKAKO EGUCHI
A1 NAGASHIMA, KENGO
A1 HONMA, YOSHITAKA
A1 KATO, KEN
A1 HAMAGUCHI, TETSUYA
A1 YAMADA, YASUHIDE
A1 SHIMADA, YASUHIRO
YR 2013
UL http://ar.iiarjournals.org/content/33/1/309.abstract
AB Background: Although bevacizumab-related hypertension has been reported as a predictive marker of therapy efficacy, an association between proteinuria and efficacy has not been reported. Patients and Methods: Eighty-two consecutive patients with metastatic colorectal cancer treated with bevacizumab as first-line treatment between July 2007 and April 2009 were examined. Results: Seventy-one patients were included in the analysis set. Proteinuria occurred in 29 patients: Grade 1 in 15 patients and grade 2 in 14 patients; no grade 3 or higher proteinuria was observed. The response rate did not increase with the severity of proteinuria (p=0.307). The median progression-free survival was 17.8 months in cases with grade 2 proteinuria, 16.0 months in those with grade 1 proteinuria, and 10.4 months in those with grade 0 proteinuria (p=0.030). In multivariate analysis with a time-dependent adjustment, there was no correlation between severity of proteinuria and survival. Conclusion: Bevacizumab-related proteinuria was not a predictive marker for patients with colorectal cancer treated with first-line bevacizumab.